Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?

Nature Clinical Practice Oncology volume 3, pages 240–241 (2006)Cite this article

boxed-textNogué M et al. (2005) Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer 41: 2241–2249

For countries in which oral tegafur with leucovorin is available, this combination is an acceptable alternative to intravenous 5-FU for metastatic colorectal cancer patients in whom single-agent 5-FU would be preferred

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Borner MM et al. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349–358

    Article  CAS  Google Scholar 

  2. Hoff PM et al. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282–2292

    Article  CAS  Google Scholar 

  3. Van Cutsem E et al. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097–4106

    Article  CAS  Google Scholar 

  4. Douillard JY et al. (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605–3616

    Article  CAS  Google Scholar 

  5. Carmichael J et al. (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617–3627

    Article  CAS  Google Scholar 

  6. Van Cutsem E et al. (2001) International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus leucovorin in the treatment of advanced colorectal cancer [abstract #522]. Proc Am Soc Clin Oncol 20

  7. Schilsky RL et al. (2002) Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 20: 1519–1526

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Medicine,

    Gregory Friberg & Richard L Schilsky

  2. Medicine and Associate Dean for Clinical Research at The University of Chicago, Chicago, IL, USA

    Gregory Friberg & Richard L Schilsky

Authors
  1. Gregory Friberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard L Schilsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard L Schilsky.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Table 1

Phase III trials of oral 5-FU analogs versus IV 5-FU in advanced colorectal cancer

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friberg, G., Schilsky, R. Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?. Nat Rev Clin Oncol 3, 240–241 (2006). https://doi.org/10.1038/ncponc0484

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0484

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing